Modified Dahuang Mouthwash, Phase 3, RTOM Prevention
Summary
A multicenter, randomized, controlled, prospective Phase 3 clinical trial (NCT07543978) is registered under NIH ClinicalTrials.gov to evaluate the safety and efficacy of Modified Dahuang Huanglian Xiexin Mouthwash versus Placebo Mouthwash for the prevention of radiotherapy-induced oral mucositis (RTOM) in patients undergoing radiotherapy. The trial is classified as Phase 3 with an anticipated start date of April 22, 2026.
“Participants will be randomly assigned to receive either the Modified Dahuang Huanglian Xiexin Mouthwash or Placebo Mouthwash.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 715 changes logged to date.
What changed
This document is a clinical trial registration entry for a Phase 3 multicenter, randomized, controlled prospective study evaluating Modified Dahuang Huanglian Xiexin Mouthwash versus placebo for the prevention of radiotherapy-induced oral mucositis. The trial will enroll participants who will be randomly assigned to receive either the active mouthwash or placebo, with the study designed to assess preventative effects on RTOM.
For pharmaceutical and clinical research stakeholders, this registry entry signals an active Phase 3 investigation in supportive-care oncology. Sponsors and investigators monitoring the Traditional Chinese Medicine pipeline in oncology should note the trial conditions (Radiotherapy-Induced Oral Mucositis, Stomatitis, Oral Mucositis) and interventions as relevant to competitive landscape awareness.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Traditional Chinese Medicine for the Prevention of Radiotherapy-Induced Oral Mucositis (RTOM)
Phase 3 NCT07543978 Kind: PHASE3 Apr 22, 2026
Abstract
This is a multicenter, randomized, controlled, prospective clinical trial designed to observe and evaluate the safety and efficacy of Modified Dahuang Huanglian Xiexin Mouthwash for the prevention of radiotherapy-induced oral mucositis (RTOM).
Participants will be randomly assigned to receive either the Modified Dahuang Huanglian Xiexin Mouthwash or Placebo Mouthwash. The study aims to assess the preventative effect on RTOM in patients undergoing radiotherapy.
Conditions: Radiotherapy-Induced Oral Mucositis, Stomatitis, Oral Mucositis, Radiotherapy Side Effects
Interventions: Modified Dahuang Huanglian Xiexin Mouthwash, Placebo Mouthwash
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.